A note to patients: Vaxil frequently receives requests from patients seeking our experimental drugs. Please keep in mind that Vaxil’s products remain unproven, investigational and in clinical trial phases. Unfortunately, Vaxil therefore does not have the ability to sell or give away any of its drugs. Furthermore, at the time, Vaxil does not have any ongoing clinical trials recruiting patients. Any patient cases sent to Vaxil can be kept on file should an applicable clinical trial be approved down the line, but there can be no assurance of this occurring. We are doing our best to advance our pipeline of drugs, but it is a lengthy process and Vaxil adheres closely to drug development regulations.
Wishing you the very best,
–The Vaxil Team
VAXIL – Creating the ideal immunotherapy
Inducing a Broad
Cancer ResistanceLearn More
Immune ResponseLearn More
Cancer Stem CellsLearn More
First Ever SP-Specific
Antibody PlatformLearn More
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is its ImMucin™ lead immunotherapy product.